Premium
Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy
Author(s) -
Krishnan V,
Rajasekaran A K
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.174
Subject(s) - medicine , leukemia , chemotherapy , clinical pharmacology , cancer therapy , drug , cancer , oncology , cancer treatment , lymphoblastic leukemia , cancer chemotherapy , pharmacology , intensive care medicine
Although chemotherapy‐based treatment of leukemia has tremendously improved survival rates in children, induction of treatment‐related side effects is a major concern in clinical oncology. The development of nanotechnology‐based drug delivery techniques to target clinically approved anticancer agents specifically to leukemic cells should diminish toxic side effects. This review aims to address the rational design of nanotherapeutics in treating hematologic malignancies with a focus on acute lymphoblastic leukemia (ALL)—the most prominent form of pediatric cancer. Clinical Pharmacology & Therapeutics (2014); 95 2, 168–178. doi: 10.1038/clpt.2013.174